In vitro and in vivo efficacy of miramistin against drug-resistant fungi

Ali Osmanov, Andrew Wise, David W. Denning

Research output: Contribution to journalArticlepeer-review

103 Downloads (Pure)


Introduction. Miramistin is a topical antiseptic with broad antimicrobial activity that was developed in the Soviet Union during the Cold War.

Aim. To investigate the antifungal activity of miramistin against clinically relevant drug-resistant fungi.

Methodology. The in vitro activity of miramistin was determined following Clinical and Laboratory Standards Institute (CLSI) guidelines. Mammalian cell toxicity was tested using a McCoy cell line and topical and systemic tolerability, and in vivo efficacy was tested using Galleria mellonella models.

Results. The minimal inhibitory concentration (MIC) range against fungi was 1.56–25 mg l−1 (GM 3.13 mg l−1 ). In the G. mellonella model, miramistin provided potent survival benefits for Candida albicans and Aspergillus fumigatus infection. Miramistin was tolerated by McCoy cell lines at concentrations up to 1000 mg l−1 and was systemically safe in G. mellonella at 2000 mg kg−1. Topical administration at 32 000 mg l−1 was well tolerated with no adverse effects.

Conclusion. These findings support further investigation of miramistin and suggest its possible use for treatment of superficial fungal infections.
Original languageUndefined
JournalJournal of medical microbiology
Early online date1 Jul 2019
Publication statusPublished - 2019

Cite this